L-lysine as adjunctive treatment in patients with schizophrenia: A single-blinded, randomized, cross-over pilot study

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Wass, Caroline ^c,d   Klamer, Daniel ^a   Katsarogiannis, Evangelos ^b   Pålsson, Erik ^a   Svensson, Lennart ^a   Fejgin, Kim ^a   Bogren, Inga Britt ^b   Engel, Jörgen A ^a   Rembeck, Birgitta ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; CITRULLINE; GLUTAMIC ACID; LYSINE; NITRIC OXIDE; PROLINE; NEUROLEPTIC AGENT; PLACEBO;

ADD ON THERAPY; ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SELF REPORT; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE BLIND PROCEDURE; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; WISCONSIN CARD SORTING TEST; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; METHODOLOGY; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LYSINE; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 79955086645     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-40     Document Type: Article

References (43)

1. Green MF, Braff DL. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol Psychiatry 2001, 49:374-384. 10.1016/S0006-3223(00)01027-1, 11239909.
2. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004, 72:41-51. 10.1016/j.schres.2004.09.009, 15531406.
3. Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg PB, Fearing K. Methylene blue adjuvant therapy of schizophrenia. Clin Neuropharmacol 1997, 20:357-363. 10.1097/00002826-199708000-00008, 9260734.
4. Klamer D, Engel JA, Svensson L. Phencyclidine-induced behaviour in mice prevented by methylene blue. Pharmacol Toxicol 2004, 94:65-72.
5. Seeman P, Guan HC, Hirbec H. Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse 2009, 63:698-704. 10.1002/syn.20647, 19391150.
6. Pålsson E, Finnerty N, Fejgin K, Klamer D, Wass C, Svensson L, Lowry J. Increased cortical nitric oxide release after phencyclidine administration. Synapse 2009, 63:1083-1088.
7. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol 2008, 31:287-292. 10.1097/WNF.0b013e3181593d45, 18836347.
8. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010, 71:138-149. 10.4088/JCP.08m04666yel, 19895780.
9. Bernstein HG, Bogerts B, Keilhoff G. The many faces of nitric oxide in schizophrenia. A review. Schizophr Res 2005, 78:69-86.
10. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
11. Johansson C, Magnusson O, Deveney AM, Jackson DM, Zhang J, Engel JA, Svensson L. The nitric oxide snthase inhibitor, L-NAME, blocks certain phencyclidine-inducedbut not amphetamie-induced effects on behaviour and brain biochemisrty in the rat. Pro Neuro-Psychopharmacol Biol Psychiat 1998, 22:1341-1360.
12. Johansson C, Deveney AM, Reif D, Jackson DM. The neuronal selective nitric oxide inhibitor AR-R 17477, blocks some effects of phencyclidine, while having no observable behavioural effects when given alone. Pharmacol Toxicol 1999, 84:226-233. 10.1111/j.1600-0773.1999.tb01487.x, 10361979.
13. Johansson C, Jackson DM, Svensson L. Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat. Psychopharmacology (Berl) 1997, 131:167-173. 10.1007/s002130050280, 9201805.
14. Klamer D, Engel JA, Svensson L. The nitric oxide synthase inhibitor, L-NAME, block phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl) 2001, 156:182-186. 10.1007/s002130100783, 11549221.
15. Klamer D, Pålsson E, Revesz A, Engel JA, Svensson L. Habituation of acoustic startle is disrupted by psychotomimetic drugs: differential dependence on dopaminergic and nitric oxide modulatory mechanisms. Psychopharmacology (Berl) 2004, 176:440-450. 10.1007/s00213-004-1901-z, 15173930.
16. Klamer D, Pålsson E, Wass C, Archer T, Svensson L. Antagonism of the nitric oxide synthase inhibitor, L-NAME, of the effects of phencyclidine on latent inhibition in taste aversion conditioning. Behav Brain Res 2005, 161:60-68. 10.1016/j.bbr.2005.01.008, 15904710.
17. Wass C, Archer T, Pålsson E, Fejgin K, Alexandersson A, Klamer D, Engel JA, Svensson L. Phencyclidine affects memory in a nitric oxide-dependent manner: Working and reference memory. Behav Brain Res 2006, 174:49-55. 10.1016/j.bbr.2006.07.003, 16935357.
18. Wass C, Archer T, Pålsson E, Fejgin K, Klamer D, Engel JA, Svensson L. Effects of phencyclidine on spatial learning and memory: nitric oxide-dependent mechanisms. Behav Brain Res 2006, 171:147-153. 10.1016/j.bbr.2006.03.036, 16677724.
19. Wass C, Klamer D, Fejgin K, Pålsson E. The importance of nitric oxide in social dysfunction. Behav Brain Res 2009, 200:113-116. 10.1016/j.bbr.2009.01.002, 19166879.
20. Wass C, Svensson L, Fejgin K, Pålsson E, Archer T, Engel JA, Klamer D. Nitric oxide synthase inhibition attenuates phencyclidine-induced disruption of cognitive flexibility. Pharmacol Biochem Behav 2008, 89:352-359. 10.1016/j.pbb.2008.01.011, 18321564.
21. White MF, Gazzola GC, Christensen HN. Cationic amino acid transport into cultured animal cells. I. Influx into cultured human fibroblasts. J Biol Chem 1982, 257:4443-4449.
22. O'Kane RL, Viña JR, Simpson I, Zaragozá R, Mokashi A, Hawkins RA. Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+. Am J Physiol Endocrinol Metab 2006, 291:E412-419.
23. Closs EI, Basha FZ, Habermeier A, Förstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997, 1:65-73. 10.1006/niox.1996.0106, 9701046.
24. Carter BW, Chicoine LG, Nelin LD. L-lysine decreases nitric oxide production and increases vascular resistance in lungs isolated from lipopolysaccharide-treated neonatal pigs. Pediatr Res 2004, 55:979-987. 10.1203/01.pdr.0000127722.55965.b3, 15155866.
25. Pålsson E, Fejgin K, Wass C, Engel JA, Svensson L, Klamer D. The amino acid L-lysine blocks the disruptive effect of phencyclidine on prepulse inhibition in mice. Psychopharmacology (Berl) 2007, 192:9-15.
26. Finnerty NJ. Electrochemical sensors: in-vitro and in-vivo analysis of brain nitric oxide and regional cerebral blood flow. PhD thesis 2008, National University of Ireland, Maynooth, Department of Chemistry.
27. Griffith RS, Norins AL, Kagan C. A multicentered study of lysine therapy in Herpes simplex infection. Dermatologica 1978, 156:257-267. 10.1159/000250926, 640102.
28. Civitelli R, Villareal DT, Agnusdei D, Nardi P, Avioli LV, Gennari C. Dietary L-lysine and calcium metabolism in humans. Nutrition 1992, 8:400-405.
29. Izquierdo OA, Parsons CM, Baker DH. Bioavailability of lysine in L-lysine.HCl. J Anim Sci 1988, 66:2590-2597.
30. Flodin NW. The metabolic roles, pharmacology, and toxicology of lysine. J Am Coll Nutr 1997, 16:7-21.
31. Spencer H, Samachson J. Effect of lysine on calcium metabolism in man. J Nutr 1963, 81:301-306.
32. Luckey EH, Rubin AL. The correction of hyponatremia in congestive heart failure. Circulation 1960, 21:229-235.
33. Anderson SR, Raiten CJ. Safety of Amino Acids Used as Dietary Supplements 1992, 22. Life Sciences Research Office, Bethesda, MD: FASEB Special Publications Office.
34. Moore S, Stein WH. A modified ninhydrin reagent for the photometric determination of amino acids and related compounds. J Biol Chem 1954, 211:907-913.
35. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch Gen Psychiatry 2007, 64:1115-1122. 10.1001/archpsyc.64.10.1115, 17909123.
36. Goldman-Rakic PS. Development of cortical circuitry and cognitive function. Child Dev 1987, 58:601-622. 10.2307/1130201, 3608641.
37. Green MF, Schooler NR, Kern RS, Frese FJ, Granberry W, Harvey PD, Karson CN, Peters N, Stewart M, Seidman LJ, Sonnenberg J, Stone WS, Walling D, Stover E, Marder SR. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry 2011,
38. Harvey PD. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev 2009, 19:324-335. 10.1007/s11065-009-9103-4, 19507034.
39. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008, 165:203-213. 10.1176/appi.ajp.2007.07010042, 18172019.
40. Harvey PD, Palmer BW, Heaton RK, Mohamed S, Kennedy J, Brickman A. Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study. Am J Psychiatry 2005, 162:110-117. 10.1176/appi.ajp.162.1.110, 15625208.
41. DeLisi LE, Szulc KU, Bertisch HC, Majcher M, Brown K. Understanding structural brain changes in schizophrenia. Dialogues Clin Neurosci 2006, 8:71-78.
42. Eack SM, Hogarty GE, Cho RY, Prasad KM, Greenwald DP, Hogarty SS, Keshavan MS. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. Arch Gen Psychiatry 2010, 67:674-682. 10.1001/archgenpsychiatry.2010.63, 20439824.
43. Kandel ER. The molecular biology of memory storage: a dialog between genes and synapses. Biosci Rep 2004, 24:475-522. 10.1007/s10540-005-2742-7, 16134023.